Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

BACKGROUND: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2. We report exploratory analyses, including the long-term outcome of candi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Hodgson, Darren R., Dougherty, Brian A., Lai, Zhongwu, Fielding, Anitra, Grinsted, Lynda, Spencer, Stuart, O’Connor, Mark J., Ho, Tony W., Robertson, Jane D., Lanchbury, Jerry S., Timms, Kirsten M., Gutin, Alexander, Orr, Maria, Jones, Helen, Gilks, Blake, Womack, Chris, Gourley, Charlie, Ledermann, Jonathan, Barrett, J. Carl
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6265286/
https://ncbi.nlm.nih.gov/pubmed/30353044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0274-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak